Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Heinz Ludwig, Michel Delforge, Thierry Facon, Hermann Einsele, Francesca Gay, Philippe Moreau, Hervé Avet-Loiseau, Mario Boccadoro, Roman Hajek, Mohamad Mohty, Michele Cavo, Meletios A. Dimopoulos, Jesús F. San-Miguel, Evangelos Terpos, Sonja Zweegman, Laurent Garderet, Mariá-Victoria Mateos, Gordon Cook, Xavier Leleu, Hartmut GoldschmidtGraham Jackson, Martin Kaiser, Katja Weisel, Niels W. C. J. van de Donk, Anders Waage, Meral Beksac, Ulf H. Mellqvist, Monika Engelhardt, Jo Caers, Christoph Driessen, Joan Bladé, Pieter Sonneveld

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.
Original languageEnglish
Pages (from-to)1542-1560
JournalLeukemia
Volume32
Issue number7
Early online date18 Dec 2017
DOIs
Publication statusPublished - 2018

Cite this